OBJECTIVES: This study presents the first report on short-and long-term outcomes in redo-port access surgery after previous port access surgery (redo-PAS-PAS) for new or recurrent mitral valve (MV) and tricuspid valve (TV) disease.
INTRODUCTION
We are witnessing a gradual increase in the number and age of patients undergoing reoperations for valvular heart disease paralleled by increased comorbidity, operative risks and quality-of-life expectations [1] . Reasons include ongoing degeneration of older bioprosthetic valves, valve repair failure and progressive native valve dysfunction in the context of previous non-valve cardiac surgery. At the same time, smaller incision and non-sternotomy approaches are becoming progressively established as excellent alternatives to conventional cardiac surgery [2] .
We initiated our total endoscopic port access programme in February 1997, shortly after the first minimally invasive valve surgery by Cosgrove et al. [3] and the first report of mitral valve (MV) repair through a minithoracotomy by Carpentier et al. [4] were described. We established this technique as our routine approach for all isolated MV and tricuspid valve (TV) surgery [5] [6] [7] , arrhythmia [8] and selected cardiac oncology surgery [9] . We subsequently extended the application of our technique to redo surgery as an excellent alternative to conventional surgery [10] .
This study provides an in-depth overview of our total endoscopic redo-port access surgery (redo-PAS) experience in 26 consecutive patients that underwent redo atrioventricular valve surgery by our current surgical team in the context of previous port access surgery (redo-PAS-PAS).
METHODS
This is a retrospective review of a single-centre prospective database. Our current surgical team performed a total of 177 redo cardiac surgery procedures for new or recurrent atrioventricular valve disease by port access between 1 February 1997 and 30 June 2014, of which 26 were operated in the context of previous port access surgery (redo-PAS-PAS). The relevant preoperative patient characteristics and clinical data are outlined in Table 1 . The indications for reoperation, which may be multiple at presentation, are described in Table 2 .
Surgical techniques and in-hospital treatment pathway
Our techniques for primary PAS and redo-PAS have been extensively described [5] [6] [7] . We perform the redo minithoracotomy through the initial primary-PAS incision ( Fig. 1) and carefully release lung adhesions from the incision site, diaphragmatic surface and pericardium for adequate access. Preoperative imaging studies to determine the severity of pleural or lung adhesions are not included in our patient evaluation and do not influence our access to decision-making.
Preoperative vascular access evaluation is routinely performed in all redo patients either by an additional contrast injection in the iliac arteries during cardiac catheterization or by MR angiography. We establish venous drainage through the right internal jugular (16-18 Fr, Optisite™, Edwards Lifesciences, Irvine, CA, USA) and femoral vein (22 or 25 Fr, Quickdraw™, Edwards Lifesciences), respectively. A femoral artery cannula with Y-arm (21 or 23 Fr, Endoreturn™, Edwards Lifesciences) is utilized for arterial flow, and an endoaortic balloon (IntraClude™, Edwards Lifesciences) is utilized for aortic occlusion and cold antegrade crystalloid cardioplegia delivery. All guidewires and cannulae are positioned under transesophageal echocardiography (TEE) guidance. We position an occlusive endoballoon (Reliant, Medtronic, Minneapolis, MN, USA) through the right internal jugular vein into the superior vena cava and snare the inferior vena cava to obtain total cardiopulmonary bypass (CPB) for primary-TV or redo-TV surgery.
We use an argon-gas surgical ablation system (Medtronic) for cryo-ablation. Long-shafted instruments, standard valve surgery techniques and left atrial appendage suture exclusion in patients with a history of transient ischaemic attack or stroke are routinely used and performed. Temporary ventricular pacing wires are placed either percutaneously through the right internal jugular vein or under endoscopic vision on the diaphragmatic ventricular epicardium, if accessible. De-airing is ensured by a venting catheter in the left atrium, continuous flooding of the operative field with CO 2 , antegrade balloon catheter venting and TEE surveillance for residual air in the left ventricle.
Cardiorespiratory support, sedation and analgesia are administered as indicated in intensive care. Postoperative chest tubes are routinely removed 48 h postoperatively and all patients receive structured in-hospital and post-discharge rehabilitation. Anti-coagulated therapy with fenprocoumon (3M Health Care Ltd) is initiated and stabilized in-hospital and continued for 3 months, with conversion to acetyl salicylic acid in the absence of persistent postoperative atrial fibrillation (AF) or mechanical valve implantation.
Follow-up
All patients attend an outpatient clinic 6-8 weeks postoperatively in addition to the continuation of care by their cardiologist and general practitioner. Post-discharge echocardiographic and clinical data were obtained by the treating physician's communication. 
Data analysis
All in-hospital data were collected prospectively. However, this study design was retrospective as the post-discharge data were collected retrospectively. In-hospital outcomes were assessed by the incidence of adverse events. Post-discharge survival and freedom from reoperation estimates were determined by KaplanMeier analysis and are expressed as a proportion ± standard error based on the intention-to-treat principle of the total population (n = 26). Data are expressed as the mean ± standard deviation and analysed with SPSS Statistics 20.0 (IBM, USA). The study was approved by the institutional ethics review committee. The authors had full access to the data and took responsibility for its integrity. All authors have read and agreed to the manuscript as written.
RESULTS

Intraoperative outcome
A total of 26 patients underwent redo-PAS-PAS. The procedures performed are outlined in Table 3 . Sternotomy conversion occurred in 5 patients (19.2%), of which 4 (15.4%) were early conversions due to extensive lung adhesions and 1 (3.8%) late conversion due to atrioventricular dehiscence during MV replacement. MV redo repairs were performed in 5 of the 10 patients (50%) who underwent previous PAS-MV repair. There were no complications in establishing vascular access or CPB. However, an iliac vein rupture occurred in 1 patient (3.8%) during post-procedure decannulation. The CPB and cross-clamp times are depicted in Table 4 . Combined procedures included additional TV repair or cryo-ablation.
Postoperative course and in-hospital outcome
Mechanical ventilation was weaned on the day of surgery in 18 patients (69.2%). Intensive care discharge within 72 h occurred in 15 patients (57.7%). Total in-hospital and 30-day mortality were 7.7% (n = 2) due to endocarditis-related multiorgan failure (EuroSCORE II = 68.2) and low cardiac output syndrome (LCOS) (EuroSCORE II = 84.1), respectively. In-hospital complications and morbidities, which were multiple in 5 patients (19.2%), are outlined in Table 5 . Surgical revisions were required in 2 patients (7.7%) and were performed via port access through the same incision. The mean length of hospitalization was 16.1 days (range: 6-74).
Survival, freedom from reoperation, clinical and echocardiographic follow-up
Updated long-term survival, freedom from MV and TV reintervention and clinical follow-up data were available for all patients (n = 26, 100%) over a mean of 48.3 ± 39.2 months postoperatively. No echocardiographic data were older than 8 months. The Kaplan-Meier curves for survival and freedom from MV and TV reintervention than includes all patients (n = 26) are presented in Fig. 2 . Late deaths occurred in 2 patients due to pneumonia (3.8 months) and progressive heart failure (12.5 months). Survival for the total patient group (n = 26) at 1 and 5 years was 88.3 and 83.9%, respectively. One patient (3.8%) required reoperation for residual MV regurgitation at 1.4 months. He underwent subsequent MV replacement via port access. Freedom from MV or TV reintervention at 5 years was 95.8%.
The long-term echocardiographic and clinical outcomes are outlined in Table 6 . The mean echocardiographic follow-up time 
DISCUSSION
The incidence of redo cardiac procedures is increasing as an ageing population presents with degeneration of bioprosthetic valve implantations, valve repair failure and native valve disease progression in the context of previous cardiac surgery [1] . Various centres now perform minimally invasive MV and TV surgery as an alternative to conventional MV surgery and new technologies that allow percutaneous and transapical valve implantation are emerging [2] . We initiated our Total Endoscopic Port Access Programme in 1997 and established this approach as our preferred technique for MV and TV surgery [5] [6] [7] [8] [9] , also after previous cardiac surgery [10] including previous port access surgery (redo-PAS-PAS). All the 26 patients reported in this series underwent redo-PAS-PAS in the context of previous primary PAS by minithoracotomy.
Early sternotomy conversion as a risk-aversion strategy change due to extensive lung adhesions occurred in 4 patients (15.4%). This limited extensive lung injury and facilitated conventional atrioventricular valve exposure. None of these patient developed subsequent respiratory morbidities. Late sternotomy conversion due to an intraoperative adverse event occurred in 1 patient (3.8%). The majority of patients in this series (n = 21 patients, 80.8%) retained the clinical and cosmetic benefits of minimally invasive surgery. Postoperative air leaks occurred in 2 patients (7.7%), which resolved within 7 days without requiring secondary surgery.
There were no complications in establishing redo vascular access or CPB, which was through either the primary-PAS incision or contralateral groin depending on preoperative imaging and clinical judgement. An iliac vein rupture occurred during decannulation in 1 patient (3.8%) and was the only adverse CPB and vascular event. The primary incision and vasculature were utilized in this case. Moments after decannulation, we noticed rapid abdominal distension with associated haemodynamic compromise. Immediate laparotomy confirmed an iliac vein rupture, which was subsequently repaired and the patient discharged after 13 days.
Postoperative LCOS was present in 3 patients (11.5%) with preoperative left ventricular ejection fractions of 65, 50 and 15% and EuroSCORE II of 19.2, 68.2 and 84.1%, respectively. All the 3 patients required MV replacement in the context of either endocarditis (n = 2, 7.7%) or ischaemic cardiomyopathy (n = 1, 3.8%). The mean ischaemic time was 88.7 min. These were high-risk patients with mortalities (n = 2, 7.7%) on Day 2 and Day 6 postoperatively and one hospital discharge (3.8%) on Day 14. We consider myocardial protection adequate and attribute these findings to premorbid risks. The 3 patients (11.5%) who required postoperative dialysis had perfusion times of 279, 239 and 103 min, respectively. Atrioventricular dehiscence occurred during redo MV replacement in the first patient and required sternotomy conversion. She was discharged after 31 days.
Permanent stroke (subarachnoid haemorrhage on the second postoperative day) occurred in 1 patient (3.8%) and was unlikely procedure related.
Re-exploration for postoperative bleeding occurred in 1 patient (3.8%). Reoperation for unexpected tissue confirmation of endocarditis post-TV repair resulted in reoperation and subsequent valve replacement (n = 1, 3.8%). Both reoperations were performed using the same incision.
We routinely advocate redo valve repair if anatomically feasible, especially in women of child-bearing age to avoid the teratogenic risks associated with vitamin K antagonist. We performed a complex redo repair that consisted of a redo annular ring placement, additional posterior leaflet resection, neochordal insertions and cleft closure in a 38-year old female with a Barlow-type MV who presented with recurrent MV incompetence 6 months after her primary MV repair. She was discharged after 7 days despite a CPB and ischaemic time of 360 and 229 min, respectively. Her clinical follow-up confirmed an ejection fraction of 55%, no residual MV regurgitation and an NYHA II clinical status at 30 months.
New onset AF occurred in 4 patients (15.4%), of which 3 (75%) were older than 70 years. Age is an established risk factor for postoperative AF and cardioplegia type has little influence [11] [12] [13] .
In total, 10 patients (38.5%) were reoperated in the context of endocarditis. Infection was successfully controlled in all surviving patients (n = 9, 90%) with no subsequent infection recurrence or need for reintervention. Aggressive annular debridement and pericardial patch reconstructions can be performed by PAS in experienced centres.
We initiate and stabilize anticoagulation and rehabilitation regimens in-hospital, which account for our mean length of hospitalization of 16.1 days.
The 30-day mortality (n = 2, 7.7%, EuroSCORE II of 84.1 and 68.2%) in our series is well below the predicted EuroSCORE I and II (22.5 and 14.2) estimates. We used both the EuroSCORE I and EuroSCORE II as predictors for operative outcome as the calibration and predictability improvements of the latter are still to be confirmed [14] . Whether minimally invasive and conventional 
Study limitations
This relatively small series reflects the outcomes of the current surgical team of a single centre with extensive primary-PAS and redo-PAS experience. We have no institutional control group as sternotomy is not performed anymore for primary or redo MV and TV procedures. We, therefore, utilized the EuroSCORE, which is standardized for sternotomy access, as a comparative control group. The enrolment period of this study was 17 years and its impact on our conclusions was not subjected to any sensitivity analyses.
CONCLUSION
We now routinely perform redo-PAS-PAS in view of its various technical advantages and good clinical outcomes. We believe that this series provides additional evidence that redo-PAS-PAS is an acceptable and very attractive redo modality in the context of previous PAS in centres with PAS experience. The majority of patients retain the benefits of minimally invasive surgery.
